Trialjectory, which uses AI to match cancer patients to clinical trials and help drug companies recruit patients, raises a $20M Series A led by Insight Partners
Emily Olsen / MobiHealthNews : Tweets: @ct_innovate , @freddytn , and @sid_healthcare Tweets: @ct_innovate : Congrats to Tzvia Bader and the TrialJectory team! The Wall Street Journal featured funding news about the $20M commitment and the work #Trialjectory is doing to change the cancer care landscape. https://www.wsj.com/... https://twitter.com/... @freddytn : .@TrialJectory Collects $20M to expand service uses #ArtificialIntelligence to Match #Cancer Patients to #ClinicalTrials #clinicaltrial #Startup, led by cancer survivor, sells to drugmakers, provides free service to patients #health #healthcare #medicine https://www.wsj.com/... Sid Shah / @sid_healthcare : .@TrialJectory scores $20M #funding to match #cancer patients to #clinicaltrials - The company helps patients find clinical trials and works with #pharma companies to limit barriers to enrollment. https://ow.ly/...
Context & Ripple Effects
Trialjectory's $20M Series A lands in a funding wave around the clinical-trial bottleneck: TrialSpark's $156M Series C pushed trials software toward drug discovery, while Inato's marketplace connects pharma companies with trial sites. Trialjectory attacks a different link in the chain — patient recruitment — with a two-sided model that is free for patients and paid for by drugmakers, led by founder and cancer survivor Tzvia Bader.
First-order effects
- Drugmakers gain a new AI-driven recruitment channel for hard-to-fill oncology trials, while cancer patients get trial matching at no cost — the revenue burden sits entirely on the pharma side.
Second-order effects
- TrialSpark and Inato now face an AI player owning the patient-facing end of the funnel, pressuring site-marketplace and trials-software models to add matching capabilities or partner rather than compete for the same pharma recruitment budgets.
Third-order effects
- If the pattern holds, clinical-trial enrollment consolidates around AI intermediaries — patient matching, site marketplaces, and QuantHealth-style trial simulation each monetizing a different layer — shifting pharma spending from sites toward software platforms that guarantee enrollment.
The trend: AI startups are systematically peeling apart the clinical-trial value chain — patients, sites, and simulation — and each layer is now drawing dedicated venture rounds.